bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Authors: de Leeuw Renée , McNair Christopher , Schiewer Matthew J. , Neupane Neermala Poudel , Brand Lucas J. , Augello Michael A. , Li Zhen , Cheng Larry C. , Yoshida Akihiro , Courtney Sean M. , Hazard E. Starr , Hardiman Gary , Hussain Maha H. , Diehl J. Alan , Drake Justin M. , Kelly Wm. Kevin , Knudsen Karen E.
Published: April 2023

LAPC4 phosphoproteomic data
Suppl. Figure S4 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

Combination therapies fail to inhibit MAPK/ERK pathway; overexpression of KRAS in Hs746T
Supplementary Figure 3 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Authors: de Leeuw Renée , McNair Christopher , Schiewer Matthew J. , Neupane Neermala Poudel , Brand Lucas J. , Augello Michael A. , Li Zhen , Cheng Larry C. , Yoshida Akihiro , Courtney Sean M. , Hazard E. Starr , Hardiman Gary , Hussain Maha H. , Diehl J. Alan , Drake Justin M. , Kelly Wm. Kevin , Knudsen Karen E.
Published: April 2023

LAPC4 GSEA analyses RNAseq data
Suppl. Figure S2 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

Next generation sequencing copy number plots for Case #2
Supplementary Figure 2 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Authors: de Leeuw Renée , McNair Christopher , Schiewer Matthew J. , Neupane Neermala Poudel , Brand Lucas J. , Augello Michael A. , Li Zhen , Cheng Larry C. , Yoshida Akihiro , Courtney Sean M. , Hazard E. Starr , Hardiman Gary , Hussain Maha H. , Diehl J. Alan , Drake Justin M. , Kelly Wm. Kevin , Knudsen Karen E.
Published: April 2023

LNCaP GSEA analyses RNAseq data.
Supplementary Figure 3 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Mahalingam Devalingam , Wang Judy S. , Hamilton Erika P. , Sarantopoulos John , Nemunaitis John , Weems Garry , Carter Laura , Hu Xiao , Schreeder Marshall , Wilkins H. Jeffrey
Published: April 2023

Baseline RORgt (RORC2) expression is variable from patient to patient.
Figure Legends from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Authors: Welti Jonathan , Sharp Adam , Yuan Wei , Dolling David , Nava Rodrigues Daniel , Figueiredo Ines , Gil Veronica , Neeb Antje , Clarke Matthew , Seed George , Crespo Mateus , Sumanasuriya Semini , Ning Jian , Knight Eleanor , Francis Jeffrey C. , Hughes Ashley , Halsey Wendy S. , Paschalis Alec , Mani Ram S. , Raj Ganesh V. , Plymate Stephen R. , Carreira Suzanne , Boysen Gunther , Chinnaiyan Arul M. , Swain Amanda , de Bono Johann S.
Published: April 2023

Supplementary Figure Legends for Figures S1 to S13
Supplementary Figures S1-S9 from Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non–Small Cell Lung Cancer
Authors: Wang Yifan , Li Nan , Jiang Wen , Deng Weiye , Ye Rui , Xu Cai , Qiao Yawei , Sharma Amrish , Zhang Ming , Hung Mien-Chie , Lin Steven H.
Published: April 2023

Supplementary Figures
Supplementary Table 4 from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
Authors: Beshiri Michael L. , Tice Caitlin M. , Tran Crystal , Nguyen Holly M. , Sowalsky Adam G. , Agarwal Supreet , Jansson Keith H. , Yang Qi , McGowen Kerry M. , Yin JuanJuan , Alilin Aian Neil , Karzai Fatima H. , Dahut William L. , Corey Eva , Kelly Kathleen
Published: April 2023

Somatic mutations in organoids and PDXs determined by WES
Figure S7 from Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Authors: Lu Haijiao , Zhang Shengzhe , Wu Jie , Chen Minjiang , Cai Mei-Chun , Fu Yujie , Li Wenfeng , Wang Jing , Zhao Xiaojing , Yu Zhuang , Ma Pengfei , Zhuang Guanglei
Published: April 2023

A. A549, PC9 and NCI-H3122 cells were treated with indicated inhibitors for 72 hours. Drug-treated adherent and supernatant cells were separately collected and subjected to TUNEL analysis. The right panel showed quantification of TUNEL positive apoptotic cells. B. A549 cells were treated with trametinib either alone or in combination with indicated inhibitors (500 nM). Cell images were recorded and cells were stained with crystal violet. C. Immunofluorescent staining of cleaved PARP (green) and nuclear 4',6-diamidino-2-phenylindole (DAPI; blue) in inhibitor-treated A549, PC9 and NCI-H3122 cells with or without DFNA5 deletion.
Table S2 from A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers
Authors: Zhu Haiyan , Gu Xiang , Xia Lu , Zhou You , Bouamar Hakim , Yang Junhua , Ding Xiaofei , Zwieb Christian , Zhang Jianan , Hinck Andrew P. , Sun Lu-Zhe , Zhu Xueqiong
Published: April 2023

Supplementary Table2. Gene Ontology Biological Processes that the differentially expressed probesets were enriched in
Figure S2 from Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Authors: Lu Haijiao , Zhang Shengzhe , Wu Jie , Chen Minjiang , Cai Mei-Chun , Fu Yujie , Li Wenfeng , Wang Jing , Zhao Xiaojing , Yu Zhuang , Ma Pengfei , Zhuang Guanglei
Published: April 2023

Cell lines with diverse oncogenic alterations were treated with indicated inhibitors.
Figure S1 from Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Authors: Lu Haijiao , Zhang Shengzhe , Wu Jie , Chen Minjiang , Cai Mei-Chun , Fu Yujie , Li Wenfeng , Wang Jing , Zhao Xiaojing , Yu Zhuang , Ma Pengfei , Zhuang Guanglei
Published: April 2023

A. A549, PC9 and NCI-H3122 cells were treated with trametinib, erlotinib and ceritinib, respectively, either alone or in combination with indicated inhibitors. B. HCC827, NCI-H358, HCC44 and NCI-1648 were treated with erlotinib, trametinib or crizotinib as indicated.
Supplementary Table 4 from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis
Authors: Prete Alessandro , Lo Agnes S. , Sadow Peter M. , Bhasin Swati S. , Antonello Zeus A. , Vodopivec Danica M. , Ullas Soumya , Sims Jennifer N. , Clohessy John , Dvorak Ann M. , Sciuto Tracey , Bhasin Manoj , Murphy-Ullrich Joanne E. , Lawler Jack , Karumanchi S. Ananth , Nucera Carmelo
Published: April 2023

Suppl. Table 4. Log2 Fold Changes (FC) of some genes differentially expressed in PTC wih BRAFV600E and hTERT mutation vs BRAFWT-PTC
Supplementary Table 3 from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis
Authors: Prete Alessandro , Lo Agnes S. , Sadow Peter M. , Bhasin Swati S. , Antonello Zeus A. , Vodopivec Danica M. , Ullas Soumya , Sims Jennifer N. , Clohessy John , Dvorak Ann M. , Sciuto Tracey , Bhasin Manoj , Murphy-Ullrich Joanne E. , Lawler Jack , Karumanchi S. Ananth , Nucera Carmelo
Published: April 2023

Suppl. Table 3. Log2 Fold Changes (FC) of some genes differentially expressed in PTC with BRAFV600E and hTERT mutation vs BRAFV600E-PTC
Supplementary Figures 1-12 Legends from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis
Authors: Prete Alessandro , Lo Agnes S. , Sadow Peter M. , Bhasin Swati S. , Antonello Zeus A. , Vodopivec Danica M. , Ullas Soumya , Sims Jennifer N. , Clohessy John , Dvorak Ann M. , Sciuto Tracey , Bhasin Manoj , Murphy-Ullrich Joanne E. , Lawler Jack , Karumanchi S. Ananth , Nucera Carmelo
Published: April 2023

Supplementary Figures 1-12 Legends
Figure S9-S12 from Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
Authors: Chen Xian , Low Kwang-Huei , Alexander Angela , Jiang Yufeng , Karakas Cansu , Hess Kenneth R. , Carey Jason P.W. , Bui Tuyen N. , Vijayaraghavan Smruthi , Evans Kurt W. , Yi Min , Ellis D. Christian , Cheung Kwok-Leung , Ellis Ian O. , Fu Siqing , Meric-Bernstam Funda , Hunt Kelly K. , Keyomarsi Khandan
Published: April 2023

supplementary figure 9-12
supplementary table S1 from Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets
Authors: Lang Stephan , Bruderek Kirsten , Kaspar Cordelia , Höing Benedikt , Kanaan Oliver , Dominas Nina , Hussain Timon , Droege Freya , Eyth Christian , Hadaschik Boris , Brandau Sven
Published: April 2023

includes table with a description of patient data
Supplemental Tables and Figures from Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
Authors: Lassman Andrew B. , Roberts-Rapp Lisa , Sokolova Irina , Song Minghao , Pestova Ekaterina , Kular Rupinder , Mullen Carolyn , Zha Zheng , Lu Xin , Gomez Erica , Bhathena Anahita , Maag David , Kumthekar Priya , Gan Hui K. , Scott Andrew M. , Guseva Maria , Holen Kyle D. , Ansell Peter J. , van den Bent Martin J.
Published: April 2023

Supplementary Table S2. Concordance of FISH and WES results. Supplementary Table S3. Point mutations identified in EGFR. Supplementary Table S4. Concordance of FISH and RT-PCR results. Supplementary Table S5. Concordance of FISH and RNAseq results. Supplementary Table S6. Concordance of FISH and IHC results. Supplementary Figure S1. Venn diagram showing overlap among EGFR assays in 206 GBMs. Supplementary Figure S2. FISH for EGFR amplification in GBM. Supplementary Figure S3. EGFR polysomy is not associated with increased EGFR expression. Supplementary Figure S4. Point mutations identified in the EGFR gene in patient samples. Supplementary Figure S5. EGFR amplification and mRNA expression are strongly associated.
Supplementary Figs and Tables from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Authors: Khanna Swati , Graef Suzanne , Mussai Francis , Thomas Anish , Wali Neha , Yenidunya Bahar Guliz , Yuan Constance , Morrow Betsy , Zhang Jingli , Korangy Firouzeh , Greten Tim F. , Steinberg Seth M. , Stetler-Stevenson Maryalice , Middleton Gary , De Santo Carmela , Hassan Raffit
Published: April 2023

Supplementary Figs and Tables
Figure S5 from Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer
Authors: Chera Bhishamjit S. , Kumar Sunil , Beaty Brian T. , Marron David , Jefferys Stuart , Green Rebecca , Goldman Emily C. , Amdur Robert , Sheets Nathan , Dagan Roi , Hayes D. Neil , Weiss Jared , Grilley-Olson Juneko E. , Zanation Adam , Hackman Trevor , Blumberg Jeffrey M. , Patel Samip , Weissler Mark , Tan Xianming M. , Parker Joel S. , Mendenhall William , Gupta Gaorav P.
Published: April 2023

Lack of correlation between ctHPV16DNA clearance at week 6 and persistent/recurrent disease
Supplementary Table S3 from Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer
Authors: Kim Tae Won , Peeters Marc , Thomas Anne , Gibbs Peter , Hool Kristina , Zhang Jianqi , Ang Agnes Lee , Bach Bruce Allen , Price Timothy
Published: April 2023

List of patients with multiple concurrent KRAS/NRAS ctDNA mutations at SFU
Supplementary Table S1 from Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer
Authors: Kim Tae Won , Peeters Marc , Thomas Anne , Gibbs Peter , Hool Kristina , Zhang Jianqi , Ang Agnes Lee , Bach Bruce Allen , Price Timothy
Published: April 2023

Comparison of clinical outcomes between plasma analysis set and intent-to-treat set for patients treated with panitumumab.
Supplementary Material from A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Authors: Tamborero David , Rubio-Perez Carlota , Muiños Ferran , Sabarinathan Radhakrishnan , Piulats Josep M. , Muntasell Aura , Dienstmann Rodrigo , Lopez-Bigas Nuria , Gonzalez-Perez Abel
Published: April 2023

Supplementary Methods, Supplementary Note, and Supplementary Figures
Supplementary information from HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma
Authors: Li Hong , Li Junjie , Chen Lei , Qi Songtao , Yu Shishi , Weng Zhijian , Hu Ziyou , Zhou Qiang , Xin Zong , Shi Linyong , Ma Liyi , Huang Annie , Lu Yuntao
Published: April 2023

Supplementary information
Supplementary Figure S3 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Authors: Lee Jong Woo , Parameswaran Janaki , Sandoval-Schaefer Teresa , Eoh Kyung Jin , Yang Dong-hua , Zhu Fang , Mehra Ranee , Sharma Roshan , Gaffney Stephen G. , Perry Elizabeth B. , Townsend Jeffrey P. , Serebriiskii Ilya G. , Golemis Erica A. , Issaeva Natalia , Yarbrough Wendell G. , Koo Ja Seok , Burtness Barbara
Published: April 2023

Supplementary Figure S3 related to Figure 5A-C. (A) Individual tumor volume changes in FaDu-xenografted mice treated with vehicle, adavosertib (30 mg/kg or 90 mg/kg, daily, p.o.), alisertib (30 mg/kg, daily, p.o.), or the combinations of alisertib with either adavosertib (30 mg/kg) or adavosertib (90 mg/kg). Tumor volume changes of all mice belonged to this study was shown in bottom panel (n = 8-9 per group). Significant differences between the combination and single drug alone are shown. (B) Body weight (g) of mice was monitored twice a week. Humane endpoint was considered when tumor volume reached 1,000 mm3 following IACUC policy. Graphs depict Mean {plus minus} SEM.
Supplementary Figure S2 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Authors: Lee Jong Woo , Parameswaran Janaki , Sandoval-Schaefer Teresa , Eoh Kyung Jin , Yang Dong-hua , Zhu Fang , Mehra Ranee , Sharma Roshan , Gaffney Stephen G. , Perry Elizabeth B. , Townsend Jeffrey P. , Serebriiskii Ilya G. , Golemis Erica A. , Issaeva Natalia , Yarbrough Wendell G. , Koo Ja Seok , Burtness Barbara
Published: April 2023

Supplementary Figure S2 related to Figure 3. Representative image of cell cycle distribution of FaDu and UNC7 cells determined by FACS analysis. Cells were treated with vehicle, adavosertib (AZD1775, 500 nM), alisertib (MLN8237, 250 nM), or the combination for 8 and 24 hours and followed by PI staining. Cell cycle distribution was assessed by FACS analysis and analyzed using FlowJo software.
Figure S2 from HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma
Authors: Li Hong , Li Junjie , Chen Lei , Qi Songtao , Yu Shishi , Weng Zhijian , Hu Ziyou , Zhou Qiang , Xin Zong , Shi Linyong , Ma Liyi , Huang Annie , Lu Yuntao
Published: April 2023

Autophagic inducers upregulate the expression of HERC3
Figure S2 from Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging
Authors: Xu Yiwen , Hosny Ahmed , Zeleznik Roman , Parmar Chintan , Coroller Thibaud , Franco Idalid , Mak Raymond H. , Aerts Hugo J.W.L.
Published: April 2023

Overall Survival Prediction Performance. The AUC values for one year and two year overall survival are shown in blue and orange respectively. The AUCs were significant for both end points with additional follow-ups (Wilcoxon rank-sums test p < 0.05 in B, C, and D).
Supplementary Data from Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma
Authors: Suzuki Yui , Saito Masato , Ishii Toshihiko , Urakawa Itaru , Matsumoto Asuka , Masaki Ayako , Ito Asahi , Kusumoto Shigeru , Suzuki Susumu , Hiura Masanori , Takahashi Takeshi , Morita Akimichi , Inagaki Hiroshi , Iida Shinsuke , Ishida Takashi
Published: April 2023

Table 1. Summary of Immunofluorescence analysis of the skin
Figure S1 from Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging
Authors: Xu Yiwen , Hosny Ahmed , Zeleznik Roman , Parmar Chintan , Coroller Thibaud , Franco Idalid , Mak Raymond H. , Aerts Hugo J.W.L.
Published: April 2023

Patient Missed Scans. Not all patients received scans within the defined time frame for follow-up. Blue rectangles indicate missed scans for each patient in Dataset A for the pretreatment and subsequent follow-ups at around 1, 3, and 6 months post radiation therapy.
Supplementary Data 3 from A Survey on Data Reproducibility and the Effect of Publication Process on the Ethical Reporting of Laboratory Research
Authors: Boulbes Delphine R. , Costello Tracy , Baggerly Keith , Fan Fan , Wang Rui , Bhattacharya Rajat , Ye Xiangcang , Ellis Lee M.
Published: April 2023

Legends for Supplementary Data
Supplementary Information from Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases
Authors: Kannan Pavitra , Kretzschmar Warren W. , Winter Helen , Warren Daniel , Bates Russell , Allen Philip D. , Syed Nigar , Irving Benjamin , Papiez Bartlomiej W. , Kaeppler Jakob , Markelc Bosjtan , Kinchesh Paul , Gilchrist Stuart , Smart Sean , Schnabel Julia A. , Maughan Tim , Harris Adrian L. , Muschel Ruth J. , Partridge Mike , Sharma Ricky A. , Kersemans Veerle
Published: April 2023

Supplementary methods and data. Supplementary Table 1. Equations of chosen models fit using ordinary least squares regression with the best Bayesian Information Criterion for iAUC90, Ktrans, and BATfrac in untreated preclinical tumors (cohort 1). Goodness of fit for each model was assessed by two measures, residuals vs fitted and Q-Q plots, which are shown in Supplementary Figure 4. Supplementary Table 2. Evaluation of model fits for iAUC90, Ktrans, and BATfrac generated from cohort 1 applied to preclinical data from cohort 2 treated with control IgG or with anti-VEGFR2 antibody DC101. Goodness of fit for each model was assessed by two measures, residuals vs fitted and Q-Q plots, which are shown in Supplementary Figures 6-7. Supplementary Table 3. Equations of chosen linear models with best Bayesian Information Criterion for iAUC90 and Ktrans in clinical tumors. Supplementary Figure 1. Signal-to-noise ratio on DCE-MRI is affected > 5 mm away from surface coil. Supplementary Figure 2. Longitudinal, repeated imaging with CT curbs tumor growth. Supplementary Figure 3. Vascular parameters (vessel length (a), tortuosity (b), and radius (c)) correlate poorly with volume of MC38 and FaDu tumors. Supplementary Figure 4. For each MR parameter of untreated preclinical tumors of cohort 1, the chosen linear model has normal residuals, as assessed by residual vs fitted plots and Q-Q plots, demonstrating goodness of fit. Supplementary Figure 5. For each MR parameter of untreated preclinical tumors of cohort 2, the tested linear model has normal residuals, as assessed by residual vs fitted plots and Q-Q plots, demonstrating goodness of fit. Supplementary Figure 6. Goodness-of-fit, as assessed by residual vs fitted plots and by Q-Q plots, for linear models applied to DC101-treated preclinical tumors of cohort 2. The chosen linear models for iAUC and BAT have residuals that exhibit departures from normality, indicating that the treatment altered these parameters. Supplementary Figure 7. For each MR parameter of clinical tumors, the chosen linear models demonstrate normal residuals, indicating goodness-of-fit.
Supplementary Figure 1 from The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
Authors: Ippen Franziska M. , Alvarez-Breckenridge Christopher A. , Kuter Benjamin M. , Fink Alexandria L. , Bihun Ivanna V. , Lastrapes Matthew , Penson Tristan , Schmidt Stephen P. , Wojtkiewicz Gregory R. , Ning Jianfang , Subramanian Megha , Giobbie-Hurder Anita , Martinez-Lage Maria , Carter Scott L. , Cahill Daniel P. , Wakimoto Hiroaki , Brastianos Priscilla K.
Published: April 2023

Western blot analysis of p-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p-MEK1/2 (Ser217/221), p-p90RSK (Ser380), p-MSK1 (Thr581) in JIMT-1 BR-3, MDA-MB-361, MDA-MB-231 BrM2 and BS-004 cell lines treated with GDC-0084 in increasing concentrations for a total of 6 hours
Supplementary Data from Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
Authors: Slovin Susan , Hussain Syed , Saad Fred , Garcia Jorge , Picus Joel , Ferraldeschi Roberta , Crespo Mateus , Flohr Penelope , Riisnaes Ruth , Lin Chihche , Keer Harold , Oganesian Aram , Workman Paul , de Bono Johann
Published: April 2023

Supplementary Data from Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer
Supplemental Table 1 from A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
Authors: Lee Valerie , Wang Judy , Zahurak Marianna , Gootjes Elske , Verheul Henk M. , Parkinson Rose , Kerner Zachary , Sharma Anup , Rosner Gary , De Jesus-Acosta Ana , Laheru Daniel , Le Dung T. , Oganesian Aram , Lilly Ellen , Brown Thomas , Jones Peter , Baylin Stephen , Ahuja Nita , Azad Nilofer
Published: April 2023

Pharmacokinetic parameters of guadecitabine and decitabine after guadecitabine injection
Supplemental Tables from Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma
Authors: Toker Aras , Nguyen Linh T. , Stone Simone C. , Yang S.Y. Cindy , Katz Sarah Rachel , Shaw Patricia A. , Clarke Blaise A. , Ghazarian Danny , Al-Habeeb Ayman , Easson Alexandra , Leong Wey L. , McCready David R. , Reedijk Michael , Guidos Cynthia J. , Pugh Trevor J. , Bernardini Marcus Q. , Ohashi Pamela S.
Published: April 2023

Supplemental Table 1: Patient clinical and specimen information. NOS, not otherwise specified; FC, flow cytometry; FA, functional assay; Bisu, bisulfilte sequencing Supplemental Table 2: Genes differentially expressed in intratumoral PD-1intICOS-hi cells, compared to PD-1hiICOSint and PD 1-ICOS-. Supplemental Table 3: Markers and antibodies used for mass cytometry.
Figure S1 from Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma
Authors: Toker Aras , Nguyen Linh T. , Stone Simone C. , Yang S.Y. Cindy , Katz Sarah Rachel , Shaw Patricia A. , Clarke Blaise A. , Ghazarian Danny , Al-Habeeb Ayman , Easson Alexandra , Leong Wey L. , McCready David R. , Reedijk Michael , Guidos Cynthia J. , Pugh Trevor J. , Bernardini Marcus Q. , Ohashi Pamela S.
Published: April 2023

Flow cytometry analysis of intratumoral Treg cells
Table S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Authors: Lauer Ulrich M. , Schell Martina , Beil Julia , Berchtold Susanne , Koppenhöfer Ursula , Glatzle Jörg , Königsrainer Alfred , Möhle Robert , Nann Dominik , Fend Falko , Pfannenberg Christina , Bitzer Michael , Malek Nisar P.
Published: April 2023

GL-ONC1 shedding analysis (patient 01).
Figure S4 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Authors: Lauer Ulrich M. , Schell Martina , Beil Julia , Berchtold Susanne , Koppenhöfer Ursula , Glatzle Jörg , Königsrainer Alfred , Möhle Robert , Nann Dominik , Fend Falko , Pfannenberg Christina , Bitzer Michael , Malek Nisar P.
Published: April 2023

Comparison of 18F-FDG-PET-CT imaging pre-virotherapy versus day 24 post virotherapy.
Supplementary Data from Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen
Authors: Baron Frédéric , Labopin Myriam , Ruggeri Annalisa , Cornelissen Jan J. , Meijer Ellen , Sengeloev Henrik , Niederwieser Dietger , De Groot Marco R. , Schouten Harry C. , Milpied Noel , Blaise Didier , Savani Bipin N. , Gluckman Eliane , Mohty Mohamad , Nagler Arnon
Published: April 2023

Supplemental table 1 : Causes of death Supplemental table 2 : Outcomes in single or double CBT recipients List of institutions reporting data included in this study.
Supplementary Data from Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell Carcinoma
Authors: Atanasova Velina S. , Pourreyron Celine , Farshchian Mehdi , Lawler Michael , Brown Christian A. , Watt Stephen A. , Wright Sheila , Warkala Michael , Guttmann-Gruber Christina , Hofbauer Josefina Piñón , Fuentes Ignacia , Prisco Marco , Rashidghamat Elham , Has Cristina , Salas-Alanis Julio C. , Palisson Francis , Hovnanian Alain , McGrath John A. , Mellerio Jemima E. , Bauer Johann W. , South Andrew P.
Published: April 2023

Figure S1-3 Table S1-2
Text S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Supplementary Text
Figure S4 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Authors: Tran Thai H. , Utama Fransiscus E. , Sato Takahiro , Peck Amy R. , Langenheim John F. , Udhane Sameer S. , Sun Yunguang , Liu Chengbao , Girondo Melanie A. , Kovatich Albert J. , Hooke Jeffrey A. , Shriver Craig D. , Hu Hai , Palazzo Juan P. , Bibbo Marluce , Auer Paul W. , Flister Michael J. , Hyslop Terry , Mitchell Edith P. , Chervoneva Inna , Rui Hallgeir
Published: April 2023

Supplementary Figure 4: Low PTHrP transcript levels are associated with poor clinical outcome in KM-plotter breast cancer dataset. Association with outcome for PTHrP transcript levels in all breast cancer breast cancer cases (N=3,951) using overall survival as endpoint and 10-year censoring from the KM-plotter datasets. Parameters used are: PTHLH Affy ID: 206300_s_at; All cases included with no restrictions except exclusion of biased arrays; Recurrence-Free survival; Auto select best cutoff; Invert Hazard ratio values below 1. Samples were dichotomized into high and low PTHrP mRNA expression based on the auto-selected cutoff value of 52 (range 1-13641) followed by Kaplan-Meier survival analysis.
Figure S3 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Authors: Tran Thai H. , Utama Fransiscus E. , Sato Takahiro , Peck Amy R. , Langenheim John F. , Udhane Sameer S. , Sun Yunguang , Liu Chengbao , Girondo Melanie A. , Kovatich Albert J. , Hooke Jeffrey A. , Shriver Craig D. , Hu Hai , Palazzo Juan P. , Bibbo Marluce , Auer Paul W. , Flister Michael J. , Hyslop Terry , Mitchell Edith P. , Chervoneva Inna , Rui Hallgeir
Published: April 2023

Supplementary Figure 3: Low PTHrP transcript levels in breast cancer are associated with poor overall survival in estrogen receptor-positive (ER+) breast cancer and in lymph node(LN)-negative breast cancer. Association with outcome for PTHrP transcript levels in breast cancer using overall survival as endpoint and 10-year censoring from the GOBO dataset. Samples were stratified into three quantiles based on PTHrP expression: PTHrP Low (log2 expression -4.97 to -0.558), PTHrP Intermediate (log2 expression -0.558 to 0.247) and PTHrP High (log2 expression 0.247 to 6.075) followed by Kaplan-Meier survival analysis of (A) LN-negative, (B) LN-positive, (C) ER-positive and (D) ER-negative tumor subgroups.
Figure S2 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Authors: Tran Thai H. , Utama Fransiscus E. , Sato Takahiro , Peck Amy R. , Langenheim John F. , Udhane Sameer S. , Sun Yunguang , Liu Chengbao , Girondo Melanie A. , Kovatich Albert J. , Hooke Jeffrey A. , Shriver Craig D. , Hu Hai , Palazzo Juan P. , Bibbo Marluce , Auer Paul W. , Flister Michael J. , Hyslop Terry , Mitchell Edith P. , Chervoneva Inna , Rui Hallgeir
Published: April 2023

Supplementary Figure 2: Positive correlation between nuclear PTHrP and nuclear pY-Stat5 protein levels across progression series of breast cancer. Scatterplot of nuclear PTHrP and nuclear pY-Stat5 protein levels in normal breast epithelia, ductal carcinoma in situ (DCIS), primary invasive breast cancer (IDC), and lymph node (LN) metastases. A positive correlation between nuclear PTHrP and nuclear pY-Stat5 protein levels was observed (R=0.536, N=92, p<0.001).
Supplementary Figure, Table & Dataset legends from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Supplementary Figure, Table & Dataset legends
Figure S1 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Authors: Tran Thai H. , Utama Fransiscus E. , Sato Takahiro , Peck Amy R. , Langenheim John F. , Udhane Sameer S. , Sun Yunguang , Liu Chengbao , Girondo Melanie A. , Kovatich Albert J. , Hooke Jeffrey A. , Shriver Craig D. , Hu Hai , Palazzo Juan P. , Bibbo Marluce , Auer Paul W. , Flister Michael J. , Hyslop Terry , Mitchell Edith P. , Chervoneva Inna , Rui Hallgeir
Published: April 2023

Supplementary Figure 1: Cytoplasmic PTHrP protein levels are reduced in breast cancer cells relative to normal breast epithelial cells. Quantification of cytoplasmic PTHrP protein levels in a progression array of normal, DCIS, primary invasive breast cancer (grades 1-3; IDC1-3), and lymph node (LN) metastases revealed that cytoplasmic PTHrP levels are lower in invasive breast cancer. *p<0.05; **p<0.02; ***p<001.
Figure S8 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S8
Figure S7 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S7
Figure S4 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S4
Table S1 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Authors: Song Kyung-A , Hosono Yasuyuki , Turner Crystal , Jacob Sheeba , Lochmann Timothy L. , Murakami Yoshiko , Patel Neha U. , Ham Jungoh , Hu Bin , Powell Krista M. , Coon Colin M. , Windle Brad E. , Oya Yuko , Koblinski Jennifer E. , Harada Hisashi , Leverson Joel D. , Souers Andrew J. , Hata Aaron N. , Boikos Sosipatros , Yatabe Yasushi , Ebi Hiromichi , Faber Anthony C.
Published: April 2023

Sup. Table 1. Genes analyzed by RNA-seq with >1 absolute Log2 fold change between PC9 parental and PC9-DTC.
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 and Figure S6 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Authors: Song Kyung-A , Hosono Yasuyuki , Turner Crystal , Jacob Sheeba , Lochmann Timothy L. , Murakami Yoshiko , Patel Neha U. , Ham Jungoh , Hu Bin , Powell Krista M. , Coon Colin M. , Windle Brad E. , Oya Yuko , Koblinski Jennifer E. , Harada Hisashi , Leverson Joel D. , Souers Andrew J. , Hata Aaron N. , Boikos Sosipatros , Yatabe Yasushi , Ebi Hiromichi , Faber Anthony C.
Published: April 2023

Figure S1. DTCs upregulate TORC1-mediated MCL-1 translation. Figure S2. High-content cell imaging assay. Figure S3. Genetic inhibition of MCL-1 is sufficient to induce apoptosis following EGFR inhibitor treatment. Figure S4. EGFR mutant tumors (PC9) respond to EGFR inhibitor/MCL-1 inhibitor (S63845) combination therapy in vivo. Figure S5. EGFR mutant tumors (HCC827) respond to EGFR inhibitor/MCL-1 inhibitor (S63845) combination therapy in vivo. Figure S6. Upregulation of MCL-1 in EGFR mutant cell lines occurs with other insults.
Figure S11 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S11
Figure S10 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S10
Table S6 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Sensitivity to nucleoside analogs gemcitabine, cladribine and clofarabine conferred by Pole proofreading domain mutations in a cell-based model
Supplementary Tables from Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Authors: Xu Jianming , Li Jie , Bai Chunmei , Xu Nong , Zhou Zhiwei , Li Zhiping , Zhou Caicun , Jia Ru , Lu Ming , Cheng Yuejuan , Mao Chenyu , Wang Wei , Cheng Ke , Su Chunxia , Hua Ye , Qi Chuan , Li Jing , Li Ke , Sun Qiaoling , Ren Yongxin , Su Weiguo
Published: April 2023

Supplementary Tables Table S1. Pharmacokinetic parameters for surufatinib in patients following dosing of 300 mg, QD Table S2. Association between baseline biomarker levels and PFS
Table S5 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Sensitivity to adjuvant treatment strategies conferred by Pole proofreading domain mutations in a cell-based model
Table S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Oligonucleotide primer sequences to generate a template for homologous recombination for transfection
Table S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

POLE mutations identified in endometrial cancers in the observation arm of the PORTEC-1 trial
Supplemental Fig S8 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

CpG-STAT3ASO stimulates immune cell activity
Supplemental Fig S7 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

Gating strategy for characterization of immune cell populations
Supplementary Figures 1-5 from Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas
Authors: Rapp Carmen , Dettling Steffen , Liu Fang , Ull Anna Theresa , Warta Rolf , Jungk Christine , Roesch Saskia , Mock Andreas , Sahm Felix , Schmidt Melissa , Jungwirth Gerhard , Zweckberger Klaus , Lamszus Katrin , Gousias Konstaninos , Kessler Almuth F. , Grabe Niels , Loehr Mario , Ketter Ralf , Urbschat Steffi , Senft Christian , Westphal Manfred , Abdollahi Amir , Debus Juergen , von Deimling Andreas , Unterberg Andreas , Simon Matthias , Herold-Mende Christel C.
Published: April 2023

Fig. S1: Workflow; Fig. S2: Representative gating strategy for TissueFAXS analysis; Fig. S3: Analysis of helper, cytotoxic and regulatory T cell infiltration and the proportion of PD-1-expressing T cells; Fig. S4: Association between the infiltration of T cells and survival; Fig. S5: Levels of tumor-infiltrating T lymphocytes (TILs) in meningiomas, separated by their localization.
Supplemental Fig S2 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

Cellular internalization of CpG-STAT3ASO
Supplemental Table 8 from Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
Authors: Frank Rieke , Scheffler Matthias , Merkelbach-Bruse Sabine , Ihle Michaela A. , Kron Anna , Rauer Michael , Ueckeroth Frank , König Katharina , Michels Sebastian , Fischer Rieke , Eisert Anna , Fassunke Jana , Heydt Carina , Serke Monika , Ko Yon-Dschun , Gerigk Ulrich , Geist Thomas , Kaminsky Britta , Heukamp Lukas C. , Clement-Ziza Mathieu , Büttner Reinhard , Wolf Jürgen
Published: April 2023

Main characteristics of the control group.
Supplementary Data from Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Authors: Lue Jennifer K. , Prabhu Sathyen A. , Liu Yuxuan , Gonzalez Yulissa , Verma Akanksha , Mundi Prabhjot S. , Abshiru Nebiyu , Camarillo Jeannie M. , Mehta Swasti , Chen Emily I. , Qiao Changhong , Nandakumar Renu , Cremers Serge , Kelleher Neil L. , Elemento Olivier , Amengual Jennifer E.
Published: April 2023

Supplemental Figures 1-7
Supplementary Data from Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Authors: Lue Jennifer K. , Prabhu Sathyen A. , Liu Yuxuan , Gonzalez Yulissa , Verma Akanksha , Mundi Prabhjot S. , Abshiru Nebiyu , Camarillo Jeannie M. , Mehta Swasti , Chen Emily I. , Qiao Changhong , Nandakumar Renu , Cremers Serge , Kelleher Neil L. , Elemento Olivier , Amengual Jennifer E.
Published: April 2023

Supplementary Figure Legends
Supplementary Data from Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor
Authors: Nag Dhrubajyoti , Bhanja Payel , Riha Randal , Sanchez-Guerrero Giselle , Kimler Bruce F. , Tsue Terance T. , Lominska Chris , Saha Subhrajit
Published: April 2023

Supplement method
Supplemental figures from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Authors: Bacac Marina , Colombetti Sara , Herter Sylvia , Sam Johannes , Perro Mario , Chen Stanford , Bianchi Roberta , Richard Marine , Schoenle Anne , Nicolini Valeria , Diggelmann Sarah , Limani Florian , Schlenker Ramona , Hüsser Tamara , Richter Wolfgang , Bray-French Katharine , Hinton Heather , Giusti Anna Maria , Freimoser-Grundschober Anne , Lariviere Laurent , Neumann Christiane , Klein Christian , Umaña Pablo
Published: April 2023

Supplemental Figure 1. Assessment of the binding characteristics and cynomolgus monkey cross-reactivity of CD20-TCB. Supplemental Figure 2. Tumor cell lysis mediated by different CD20-targeting TCB antibodies. Supplemental Figure 3. T-cell and B-cell counts along with E:T ratio upon CD20-TCB treatment of primary bone marrow aspirates from patients with lymphoma and leukemia. Supplemental Figure 4. Quantification of interactions between T-cells and tumor cells from live imaging experiments and kinetic analysis of T-cell activation and exhaustion marker expression. Supplemental Figure 5. Secretion of cytokines, cytotoxic granules and T-cell proliferation upon tumor lysis. Supplemental Figure 6. Assessment of the cytokine-mediated endothelial cell activation. Supplemental Figure 7. Characterization of stem cell humanized mice (HSC-NSG) generated in house.
Supplementary tables and figures from Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling
Authors: Dowless Michele , Lowery Caitlin D. , Shackleford Terry , Renschler Matthew , Stephens Jennifer , Flack Robert , Blosser Wayne , Gupta Simone , Stewart Julie , Webster Yue , Dempsey Jack , VanWye Alle B. , Ebert Philip , Iversen Philip , Olsen Jonathan B. , Gong Xueqian , Buchanan Sean , Houghton Peter , Stancato Louis
Published: April 2023

Supplementary Tables S1-S3, Figures S1-S4
Supplementary Data from Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays
Authors: Coombs Catherine C. , Gillis Nancy K. , Tan Xianming , Berg Jonathan S. , Ball Markus , Balasis Maria E. , Montgomery Nathan D. , Bolton Kelly L. , Parker Joel S. , Mesa Tania E. , Yoder Sean J. , Hayward Michele C. , Patel Nirali M. , Richards Kristy L. , Walko Christine M. , Knepper Todd C. , Soper John T. , Weiss Jared , Grilley-Olson Juneko E. , Kim William Y. , Earp H. Shelton , Levine Ross L. , Papaemmanuil Elli , Zehir Ahmet , Hayes D. Neil , Padron Eric
Published: April 2023

Supplementary data file
Supplementary Table S6 from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Excel file containing deferentially expressed genes (RNA-seq) for comparisons of CUSG006, -007, and -012 tumors.
Table S4 from The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Authors: Barry Peter , Vatsiou Alexandra , Spiteri Inmaculada , Nichol Daniel , Cresswell George D. , Acar Ahmet , Trahearn Nicholas , Hrebien Sarah , Garcia-Murillas Isaac , Chkhaidze Kate , Ermini Luca , Huntingford Ian Said , Cottom Hannah , Zabaglo Lila , Koelble Konrad , Khalique Saira , Rusby Jennifer E. , Muscara Francesca , Dowsett Mitch , Maley Carlo C. , Natrajan Rachael , Yuan Yinyin , Schiavon Gaia , Turner Nicholas , Sottoriva Andrea
Published: April 2023

Targeted sequencing mutations cancer cell fractions used in Figure 2A and 4A
Supplementary Table S3 from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Excel file will all damaging mutations called by Exome-seq analysis of SGC tumor tissue.
Table S2 from The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Authors: Barry Peter , Vatsiou Alexandra , Spiteri Inmaculada , Nichol Daniel , Cresswell George D. , Acar Ahmet , Trahearn Nicholas , Hrebien Sarah , Garcia-Murillas Isaac , Chkhaidze Kate , Ermini Luca , Huntingford Ian Said , Cottom Hannah , Zabaglo Lila , Koelble Konrad , Khalique Saira , Rusby Jennifer E. , Muscara Francesca , Dowsett Mitch , Maley Carlo C. , Natrajan Rachael , Yuan Yinyin , Schiavon Gaia , Turner Nicholas , Sottoriva Andrea
Published: April 2023

Purity and ploidy estimates per sample
Supplementary Figure S6 from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Fig. S6. Reproducibility of sphere formation by tumor subpopulations sorted from CUSG PDX models.
Supplementary Figure S5 from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Fig. S5. Representative sphere images for sorted PDX tumor subpopulations grown in non-adherent serum-free culture conditions. Scale bar = 200 µm.